The companies said the name is derived from the Latinwords via, meaning path, and tris, meaning three, to signify the company’s three core goals: expanding access to medicines, leading by innovating to meet patient needs and being a trusted partner for the healthcare community.
The companies have not yet announced where Viatris will be headquartered, besides that it will be in the U.S., according to the Pittsburgh Post-Gazette.
Mylan and Pfizer said more information on Viatris, including the company’s full executive management team, board of directors, stock symbol and logo will be announced at a later date.
The merger is expected to be finalized in mid-2020.
Read the full news release here.
More articles on pharmacy:
Endo CEO to retire
Trump administration sues Gilead
CVS to close 22 ‘underperforming’ stores
